Settled

Do GLP-1 receptor agonists improve all-cause mortality versus placebo?

Mostly studied in type 2 & unspecified diabetes. Also asked against other treatments.

Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →

Where the evidence stands

Very likely. So far, repeated by independent trials.

NoUnsureYes
Belief
0.87 (range 0.60–1.00)
Trials for
7
Trials against
1
Inconclusive
2

Already under way

The evidence so far

Registered trials
48
With posted results
13
Published papers
16

Of 31 decided analyses: 14 favor glp-1 receptor agonists, 15 find no difference, 2 favor the comparator.

Papers

Trials

See every trial in the evidence map →